EGFR ligand Angiogenin predicts response to ALK5 inhibition in pancreatic cancer via a TNF-α paracrine axis in tumor-associated macrophages.

Oncogene · 2026 · PMC13167465 · PMID 41975075

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

In the phase 2b/randomized phase 2 H9H-MC-JBAJ trial involving patients with newly diagnosed unresectable PDAC, the addition of the ALK5 inhibitor galunisertib to gemcitabine demonstrated a positive trend in improving overall survival (OS) compared to gemcitabine alone [ 9 ].

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.